SCHEMBL16722802

SCHEMBL16722802

CC(C)(C)C(=O)Nc1cccc(NC(=O)C(C)(C)C)c1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.76
L3MBTL1 Q9Y468 2/20 0.68
KDM4E B2RXH2 3/20 0.63
ALDH1A1 P00352 3/20 0.58
MAPT P10636 2/20 0.58
LCK P06239 1/20 0.57
CTSL P07711 1/20 0.57
PTPRC P08575 1/20 0.57
PTPN2 P17706 1/20 0.57
PTPN1 P18031 1/20 0.57
CTSS P25774 1/20 0.57
PTPN13 Q12923 1/20 0.57
POLB P06746 2/20 0.55
LMNA P02545 2/20 0.55
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
GPR35 Q9HC97 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16350809 0.92 L3MBTL1 (0.72) NPSR1L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL13899725 0.92 NPSR1 (0.67) NPSR1L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL19501628 0.89 NPSR1 (0.63) NPSR1L3MBTL1KDM4EMAPTLCK
SCHEMBL1131584 0.88 NPSR1 (0.67) NPSR1L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL30718955 0.88 NPSR1 (0.67) NPSR1L3MBTL1KDM4EALDH1A1MEN1
SCHEMBL9123617 0.88 NPSR1 (0.67) NPSR1L3MBTL1KDM4EALDH1A1MEN1
SCHEMBL11759504 0.88 RAB9A (0.68) NPSR1L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL11873457 0.88 NPSR1 (0.61) NPSR1L3MBTL1KDM4EALDH1A1MAPT
SCHEMBL11878225 0.88 NPSR1 (0.61) NPSR1L3MBTL1KDM4EALDH1A1LCK
SCHEMBL28419749 0.88 NPSR1 (0.61) NPSR1L3MBTL1KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023230541-A1 PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY VIIV HEALTHCARE COMPANY (US) 2023-11-30 WO disclosed
US-9593197-B2 Trigger-responsive chain-shattering polymers THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2017-03-14 US disclosed
US-9593197-B2 Trigger-responsive chain-shattering polymers THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2017-03-14 US disclosed
US-20150141453-A1 Trigger-Responsive Chain-Shattering Polymers THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2015-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141453-A1 Trigger-Responsive Chain-Shattering Polymers SGTA, FUS, EWSR1 NPSR1 2492/4885L3MBTL1 1786/4885KDM4E 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.